Abstract
Few companies are launched on a stronger footing than ScinoPharm. Short of a war, natural disaster, or a destructive feud among the management team, there are few imaginable scenarios under which this new company could fail. This active pharmaceutical ingredient (API) producer is setting up world-class facilities in Taiwan at a cost of $200 million. It is doing so much faster and much cheaper than it could in advanced industrialized countries. research and multiproduct manufacturing complex, built and operated to the highest standards, will be the world's largest nonbranded API plant. As for the market outlook, there is already a long backlog of orders, and the market for drug ingredients is both promising and growing rapidly. The pie is expanding. We need more producers in this industry, says Jo Shen, president and chief executive officer of the Tainan-based firm. firm's kilo lab—so named for the kilogram quantities of material it can ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
